

Imre Noth

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11015246/imre-noth-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

108
papers

6,950
citations

39
h-index

83
g-index

140
ext. papers

8,905
ext. citations

10.4
avg, IF

5.42
L-index

#	Paper	IF	Citations
108	Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort.. <i>Lung</i> , 2022 , 200, 11	2.9	0
107	Associations of D-Dimer with Computed Tomographic Lung Abnormalities, Serum Biomarkers of Lung Injury, and Forced Vital Capacity: MESA Lung Study. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 1839-1848	4.7	1
106	Radiomics-based assessment of idiopathic pulmonary fibrosis is associated with genetic mutations and patient survival. <i>Journal of Medical Imaging</i> , 2021 , 8, 031903	2.6	0
105	Antibody-mediated depletion of CCR10+EphA3+ cells ameliorates fibrosis in IPF. <i>JCI Insight</i> , 2021 , 6,	9.9	3
104	Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 1841-1851	27.4	12
103	Detection and Early Referral of Patients With Interstitial Lung Abnormalities: An Expert Survey Initiative. <i>Chest</i> , 2021 ,	5.3	4
102	MicroRNA and protein-coding gene expression analysis in idiopathic pulmonary fibrosis yields novel biomarker signatures associated to survival. <i>Translational Research</i> , 2021 , 228, 1-12	11	1
101	Differential Responses to Targeting Matrix Metalloproteinase 9 in Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 458-470	10.2	6
100	Proportion of Idiopathic Pulmonary Fibrosis Risk Explained by Known Common Genetic Loci in European Populations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 775-778	10.2	4
99	Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitis. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	7
98	Blood Transcriptomics Predicts Progression of Pulmonary Fibrosis and Associated Natural Killer Cells. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 204, 197-208	10.2	7
97	50-gene risk profiles in peripheral blood predict COVID-19 outcomes: A retrospective, multicenter cohort study. <i>EBioMedicine</i> , 2021 , 69, 103439	8.8	1
96	Antimicrobial Therapy and Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis-Reply. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 1071-1072	27.4	
95	Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial. <i>European Respiratory Journal</i> , 2021 , 58,	13.6	2
94	Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort. <i>BMC Pulmonary Medicine</i> , 2020 , 20, 64	3.5	21
93	Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy - the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical trial. <i>Respiratory Research</i> , 2020 , 21, 68	7.3	15
92	Sepsis-associated acute respiratory distress syndrome in individuals of European ancestry: a genome-wide association study. <i>Lancet Respiratory Medicine</i> , 2020 , 8, 258-266	35.1	10

91	A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis. <i>Chest</i> , 2020 , 157, 1506-1512	5.3	18
90	Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2020 , 158, 1526-1534	5.3	11
89	CPAP Adherence, Mortality, and Progression-Free Survival in Interstitial Lung Disease and OSA. <i>Chest</i> , 2020 , 158, 1701-1712	5.3	3
88	Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 201, 564-574	10.2	81
87	The Pulmonary Fibrosis Foundation Patient Registry. Rationale, Design, and Methods. <i>Annals of the American Thoracic Society</i> , 2020 , 17, 1620-1628	4.7	8
86	Myositis-specific Antibodies Identify A Distinct Interstitial Pneumonia with Autoimmune Features Phenotype. <i>European Respiratory Journal</i> , 2020 ,	13.6	6
85	Automated CT Analysis of Major Forms of Interstitial Lung Disease. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	3
84	Circulating Plasma Biomarkers of Progressive Interstitial Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 201, 250-253	10.2	14
83	Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. <i>Lancet Respiratory Medicine</i> , 2019 , 7, 771-779	35.1	34
82	Novel idiopathic pulmonary fibrosis susceptibility variants revealed by deep sequencing. <i>ERJ Open Research</i> , 2019 , 5,	3.5	14
81	Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2019 , 156, 706-714	5.3	21
80	Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 200, 199-208	10.2	53
79	T cell Co-Stimulatory molecules ICOS and CD28 stratify idiopathic pulmonary fibrosis survival. <i>Respiratory Medicine: X</i> , 2019 , 1, 100002-100002	1.6	0
78	Genetics of Idiopathic Pulmonary Fibrosis. <i>American Journal of the Medical Sciences</i> , 2019 , 357, 379-383	2.2	8
77	Integrating Genomics Into Management of Fibrotic Interstitial Lung Disease. <i>Chest</i> , 2019 , 155, 1026-1040	9.3	16
76	Overlap of Genetic Risk between Interstitial Lung Abnormalities and Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 200, 1402-1413	10.2	37
75	Rare Protein-Altering Telomere-related Gene Variants in Patients with Chronic Hypersensitivity Pneumonitis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 200, 1154-1163	10.2	45
74	Low Dose Carbon Monoxide Exposure in Idiopathic Pulmonary Fibrosis Produces a CO Signature Comprised of Oxidative Phosphorylation Genes. <i>Scientific Reports</i> , 2019 , 9, 14802	4.9	10

73	Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials. <i>European Respiratory Journal</i> , 2019 , 54,	13.6	16
72	Prognosticating Outcomes in Interstitial Lung Disease by Mediastinal Lymph Node Assessment. An Observational Cohort Study with Independent Validation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 199, 747-759	10.2	22
71	Telomere Length and Use of Immunosuppressive Medications in Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 200, 336-347	10.2	41
70	Anti-RNA binding protein positivity in idiopathic interstitial pneumonia. <i>Respiratory Medicine</i> , 2019 , 146, 23-27	4.6	1
69	Reply to Lescoat et al. and to Khamis et al. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 199, 1041-1042	10.2	
68	Computed Tomography Honeycombing Identifies a Progressive Fibrotic Phenotype with Increased Mortality across Diverse Interstitial Lung Diseases. <i>Annals of the American Thoracic Society</i> , 2019 , 16, 580-588	4.7	41
67	Telomere length and genetic variant associations with interstitial lung disease progression and survival. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	67
66	African-American race and mortality in interstitial lung disease: a multicentre propensity-matched analysis. <i>European Respiratory Journal</i> , 2018 , 51,	13.6	16
65	CT-Pathologic Correlation of Major Types of Pulmonary Fibrosis: Insights for Revisions to Current Guidelines. <i>American Journal of Roentgenology</i> , 2018 , 210, 1034-1041	5.4	17
64	Phenotypic Clusters Predict Outcomes in a Longitudinal Interstitial Lung Disease Cohort. <i>Chest</i> , 2018 , 153, 349-360	5.3	26
63	N-acetylcysteine exposure is associated with improved survival in anti-nuclear antibody seropositive patients with usual interstitial pneumonia. <i>BMC Pulmonary Medicine</i> , 2018 , 18, 30	3.5	3
62	Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2018 , 6, 707-714	35.1	74
61	Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis: An International Modified Delphi Survey. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 197, 1036-1044	10.2	109
60	A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2018 , 153, 94-104	5.3	47
59	CT Features of the Usual Interstitial Pneumonia Pattern: Differentiating Connective Tissue Disease-Associated Interstitial Lung Disease From Idiopathic Pulmonary Fibrosis. <i>American Journal of Roentgenology</i> , 2018 , 210, 307-313	5.4	53
58	PD-1 up-regulation on CD4 T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF- β production. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	109
57	Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK trial. <i>BMJ Open Respiratory Research</i> , 2018 , 5, e000325	5.6	13
56	Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in the USA. <i>European Respiratory Journal</i> , 2018 , 52,	13.6	20

55	Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study. <i>JAMA Oncology</i> , 2017 , 3, 636-651	13.4	236
54	Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 208-219	10.2	89
53	Interstitial Pneumonia With Autoimmune Features: Value of Histopathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2017 , 141, 960-969	5	22
52	The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processes. <i>Scientific Reports</i> , 2017 , 7, 46560	4.9	28
51	CT Findings, Radiologic-Pathologic Correlation, and Imaging Predictors of Survival for Patients With Interstitial Pneumonia With Autoimmune Features. <i>American Journal of Roentgenology</i> , 2017 , 208, 1229-1236	5.4	37
50	N-acetylcysteine for idiopathic pulmonary fibrosis: the door is still open. <i>Lancet Respiratory Medicine</i> , 2017 , 5, e1-e2	35.1	12
49	Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study. <i>Lancet Respiratory Medicine</i> , 2017 , 5, 869-880	35.1	142
48	Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis. <i>ERJ Open Research</i> , 2017 , 3,	3.5	46
47	Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study. <i>Lancet Respiratory Medicine</i> , 2017 , 5, 857-868	35.1	59
46	CT findings associated with survival in chronic hypersensitivity pneumonitis. <i>European Radiology</i> , 2017 , 27, 5127-5135	8	25
45	Autoimmune Hypothyroidism As a Predictor of Mortality in Chronic Hypersensitivity Pneumonitis. <i>Frontiers in Medicine</i> , 2017 , 4, 170	4.9	6
44	Expression profiling elucidates a molecular gene signature for pulmonary hypertension in sarcoidosis. <i>Pulmonary Circulation</i> , 2016 , 6, 465-471	2.7	9
43	Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease. <i>Respiratory Medicine</i> , 2016 , 121, 117-122	4.6	57
42	Response. <i>Chest</i> , 2016 , 149, 600-601	5.3	
41	Skewed Lung CCR4 to CCR6 CD4 T Cell Ratio in Idiopathic Pulmonary Fibrosis Is Associated with Pulmonary Function. <i>Frontiers in Immunology</i> , 2016 , 7, 516	8.4	19
40	Pharmacogenetics and interstitial lung disease. <i>Current Opinion in Pulmonary Medicine</i> , 2016 , 22, 456-65	3	8
39	When Is It More Than Just a Spicy Meal?. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2016 , 26, 499-500	2.1	
38	Characterisation of patients with interstitial pneumonia with autoimmune features. <i>European Respiratory Journal</i> , 2016 , 47, 1767-75	13.6	159

37	Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2015 , 45, 1393-402	13.6	46
36	An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. <i>European Respiratory Journal</i> , 2015 , 46, 976-87	13.6	541
35	Sphingosine-1-phosphate lyase is an endogenous suppressor of pulmonary fibrosis: role of S1P signalling and autophagy. <i>Thorax</i> , 2015 , 70, 1138-48	7.3	46
34	TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 192, 1475-82	10.2	187
33	Thyroid Disease Is Prevalent and Predicts Survival in Patients With Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2015 , 148, 692-700	5.3	36
32	A functional genomic model for predicting prognosis in idiopathic pulmonary fibrosis. <i>BMC Pulmonary Medicine</i> , 2015 , 15, 147	3.5	27
31	The mitochondrial cardiolipin remodeling enzyme lysocardiolipin acyltransferase is a novel target in pulmonary fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014 , 189, 1402-15	10.2	31
30	Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation. <i>Lancet Respiratory Medicine</i> , 2014 , 2, 557-65	35.1	151
29	Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014 , 189, 214-22	10.2	159
28	Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. <i>Lancet Respiratory Medicine</i> , 2014 , 2, 548-56	35.1	252
27	Idiopathic pulmonary fibrosis: early detection and referral. <i>Respiratory Medicine</i> , 2014 , 108, 819-29	4.6	27
26	Reply: rationale for anticoagulant therapy of pulmonary fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014 , 189, 363	10.2	1
25	Association between MUC5B and TERT polymorphisms and different interstitial lung disease phenotypes. <i>Translational Research</i> , 2014 , 163, 494-502	11	50
24	Gastroesophageal Reflux and IPF 2014 , 281-296		
23	Targeting sphingosine kinase 1 attenuates bleomycin-induced pulmonary fibrosis. <i>FASEB Journal</i> , 2013 , 27, 1749-60	0.9	67
22	Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. <i>Lancet Respiratory Medicine</i> , 2013 , 1, 369-76	35.1	276
21	Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. <i>Lancet Respiratory Medicine</i> , 2013 , 1, 309-317	35.1	341
20	GERD and idiopathic pulmonary fibrosis: cause or effect. <i>Current Respiratory Care Reports</i> , 2013 , 2, 260-267		2

19	Reply: A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis: a hidden subgroup?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 187, 1030	10.2	2
18	Warfarin in idiopathic pulmonary fibrosis: friend or foe, is it a matter of genes and heparin? : a reply to Tzouvelekis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 187, 214	10.2	7
17	Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 309, 2232-9	27.4	286
16	Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. <i>Science Translational Medicine</i> , 2013 , 5, 205ra136	17.5	170
15	Peripheral blood biomarkers in idiopathic pulmonary fibrosis. <i>Translational Research</i> , 2012 , 159, 218-27	11	80
14	Peripheral blood gene expression as a novel genomic biomarker in complicated sarcoidosis. <i>PLoS ONE</i> , 2012 , 7, e44818	3.7	54
13	Pathologic quantification of connective tissue disease-associated versus idiopathic usual interstitial pneumonia. <i>Archives of Pathology and Laboratory Medicine</i> , 2012 , 136, 1253-8	5	25
12	A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 186, 88-95	10.2	350
11	Reply: Is Warfarin the Right Anticoagulant in Idiopathic Pulmonary Fibrosis?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 186, 693-694	10.2	4
10	Interstitial Lung Disease and Antinuclear Antibody: Response. <i>Chest</i> , 2012 , 141, 1361	5.3	1
9	Interstitial lung disease and gastroesophageal reflux disease: key role of esophageal function tests in the diagnosis and treatment. <i>Arquivos De Gastroenterologia</i> , 2011 , 48, 91-7	1.3	27
8	A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis. <i>New England Journal of Medicine</i> , 2011 , 364, 1576-7	59.2	157
7	Autoimmune-featured interstitial lung disease: a distinct entity. <i>Chest</i> , 2011 , 140, 1292-1299	5.3	193
6	The HLA class II Allele DRB1*1501 is over-represented in patients with idiopathic pulmonary fibrosis. <i>PLoS ONE</i> , 2011 , 6, e14715	3.7	39
5	Genesis of Some Histologic, BAL, and Auscultatory Features of Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2008 , 133, 585-586	5.3	
4	Acute exacerbations of idiopathic pulmonary fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007 , 176, 636-43	10.2	823
3	Recent advances in idiopathic pulmonary fibrosis. <i>Chest</i> , 2007 , 132, 637-50	5.3	79
2	Churg-Strauss syndrome. <i>Lancet, The</i> , 2003 , 361, 587-94	40	299

- 1 Genome-wide association study across five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosis

o